AI-generated analysis. Always verify with the original filing.
Sunshine Biopharma, Inc. filed an 8-K on February 20, 2026, disclosing matters submitted to a vote of security holders under Item 5.07. Dr. Steve N. Slilaty, as the holder of the majority of the voting power of the stockholders, took action on February 18, 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
Submission of Matters to a Vote of Security Holders. On February 18, 2026, Dr. Steve N. Slilaty, as the holder of the majority of the voting power of the stockh